GEN uncovers seven biopharma-related trends based on interviews with experts and other industry stakeholders, as well as ...

Eli Lilly is joining in a lawsuit filed by the Outsourcing Facilities against the FDA, aiming to reverse the FDA's October 2024 determination that the shortage has been resolved, which would allow ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Trans Rights To Be Marquee Fight For House Republicans Believing voters in the 2024 elections rejected Democrats’ more inclusive positions on transgender rights, Republicans appear ready in 2025 to ...

Novo Nordisk’s Ozempic and Wegovy continue to outpace Eli Lilly’s Mounjaro and Zepbound, even though the latter are demonstrably more effective in clinical trials. The most recent earnings reports ...

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...

DOVBLERON® was approved by China’s National Medical Products Administration (NMPA): 1) for the treatment of adult patients with locally advanced or metastatic ROS1-positive NSCLC who have previously ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.

Eli Lilly is seeking to end a lawsuit filed by a pharmacy trade group against the Food and Drug Administration (FDA) by ...

A high dividend and inclusion in the Dow Jones Average 30 may create the impression of a foolproof investment, but those are ...

The drug and biotech industry had a tough time in the past couple of months after Trump announced the appointment of Robert F ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...